Prevalence of transfusion transmitted virus (TTV) genotypes among HCC patients in Qaluobia governorate

Hafez, Mohamed M.; Shaarawy, Sabry; Hassan, Amr; Salim, Rabab Fawzi; Salam, Fatma M Abd El; Ali, Arwa

doi:10.1186/1743-422x-4-135

Cited by 16 publications

(10 citation statements)

References 32 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that TTV infection did not cause severe liver damage in two groups of hepatitis patients and healthy group. This was indicated by a very moderate elevation in ALT level in the disease groups, which in cirrhotic patients due to HCV showed a high ALT level than those of chronic liver disease due to HBV and HCV (31). While reviewing our findings in reference to various other studies, we found that our data are in agreement with several other reports.…”

Section: Discussionsupporting

confidence: 92%

Molecular Epidemiology of Torque Teno Virus (TTV) Isolated from in Healthy and Subjects with Chronic Hepatitis B and C in Jahrom City of Iran

et al. 2013

View full text Add to dashboard Cite

Background and Aims: Torque teno virus (TTV) is a DNA virus that isolated from the serum of a Japanese patient without A-G transfusion-transmitted hepatitis and other etiology. TTV is detectable in plasma and peripheral blood mononuclear cells, different body fluids and secretions such as stools, saliva, semen, vaginal fluid. The genome exhibits high diversity that has enabled the determination of several genotypes and subtypes and at least 30 genotypes have been identified. TTV might be seen as a risk factor in acute and chronic hepatitis, but it is not clear. Coinfection of TTV and HBV or TTV and HCV is common, because these viruses share the same transmission routes such as blood transfusion. The aim of this study was to determine the prevalence of TTV in patients with chronic HBV and HCV in the Southern of Iran and evaluate effect of TTV infection on the liver diseases. Materials and Methods: Serum samples collected from all hepatitis patients and healthy control subjects were included for serological tests for hepatitis B and C viruses. Briefly, DNA was isolated from serum of collected peripheral blood mononuclear cells (PBMC) of patients and carry out Semi Nested PCR Detection for TTV DNA. Results: These results showed the significant relationship between TTV and the patients that had chronic HBV and HCV (p<0.01). Conclusion: According to the result of this study, the prevalence of TTV in patients with chronic HBV and HCV in the southern of Iran was 50.8 and 66.5 %, respectively. These results were comparable to those reported in previous studies ranging from 20% to 75.7% for hepatitis C and from 40% to 75% for hepatitis B patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Molecular Epidemiology of Torque Teno Virus (TTV) Isolated from in Healthy and Subjects with Chronic Hepatitis B and C in Jahrom City of Iran

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The Torque teno transfusion-transmitted circoviruses are widely spread worldwide [76,140,404,423]. These agents emerge as the inducers of anti-DNA auto-antibodies and as the causative agents of "idiopathic" inflammatory myositis [35,121,122].…”

Section: The Resident Viral Flora (Endogenous Retroviruses Potentialmentioning

confidence: 99%

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

Sinkovics

Horváth

2008

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Based on personal acquaintances and experience dating back to the early 1950s, the senior author reviews the history of viral therapy of cancer. He points out the difficulties encountered in the treatment of human cancers, as opposed by the highly successful viral therapy of experimentally maintained tumors in laboratory animals, especially that of ascites carcinomas in mice. A detailed account of viral therapy of human tumors with naturally oncolytic viruses follows, emphasizing the first clinical trials with viral oncolysates. The discrepancy between the high success rates, culminating in cures, in the treatment of tumors of laboratory animals, and the moderate results, such as stabilizations of disease, partial responses, very rare complete remissions, and frequent relapses with virally treated human tumors is recognized. The preclinical laboratory testing against established human tumor cell lines that were maintained in tissue cultures for decades, and against human tumors extricated from their natural habitat and grown in xenografts, may not yield valid results predictive of the viral therapy applied against human tumors growing in their natural environment, the human host. Since the recent discovery of the oncosuppressive efficacy of bacteriophages, the colon could be regarded as the battlefield, where incipient tumor cells and bacteriophages vie for dominance. The inner environment of the colon will be the teaching ground providing new knowledge on the value of the anti-tumor efficacy of phage-induced innate anti-tumor immune reactions. Genetically engineered oncolytic viruses are reviewed next. The molecular biology of viral oncolysis is explained in details. Elaborate efforts are presented to elucidate how gene product proteins of oncolytic viruses switch off the oncogenic cascades of cancer cells. The facts strongly support the conclusion that viral therapy of human cancers will remain in the front lines of modern cancer therapeutics. It may be a combination of naturally oncolytic viruses and wild-type viruses rendered oncolytic and harmless by genetic engineering, that will induce complete remissions of human tumors. It may be necessary to co-administer certain chemotherapeutic agents, advanced cancer vaccines, or even immune lymphocytes, and targeted therapeuticals, to ascertain, that remissions induced by the viral agents will remain complete and durable; will co-operate with anti-tumor host immune reactions, and eventually will result in cures of advanced metastatic human cancers.

show abstract

“…TTV is an ubiquitous virus revealed in more than 50% of the general human population throughout the world [ 4 - 6 ] and nearly 90% of pongid populations [ 7 ]. Co-infection of single individuals with TTV isolates belonging to one or several phylogenetic groups occurs frequently [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…TTV has been suggested to be a causative agent of several diseases such as acute respiratory diseases [ 16 ], liver diseases [ 5 , 6 ], AIDS [ 17 ] and cancer [ 18 ], however, without any convincing support. One of current hypothesis suggests a key role of TTV in development of autoimmune reactions [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Torque Teno Virus (TTV) distribution in healthy Russian population

Vasilyev¹,

Trofimov²,

Tonevitsky

et al. 2009

Virol J

View full text Add to dashboard Cite

Background: Torque teno virus (TTV) is a circular, single-stranded DNA virus that chronically infects healthy individuals of all ages worldwide. There is a lot of data on the prevalence and genetic heterogeneity of TTV in healthy populations and in patients with various diseases now available. However, little is known about TTV load among healthy human population. In this study we analyzed TTV load in the group of 512 Russian elite athletes, who are supposed to be, by some standards, the healthiest part of the human population.

show abstract

Prevalence of transfusion transmitted virus (TTV) genotypes among HCC patients in Qaluobia governorate

Cited by 16 publications

References 32 publications

Molecular Epidemiology of Torque Teno Virus (TTV) Isolated from in Healthy and Subjects with Chronic Hepatitis B and C in Jahrom City of Iran

Molecular Epidemiology of Torque Teno Virus (TTV) Isolated from in Healthy and Subjects with Chronic Hepatitis B and C in Jahrom City of Iran

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

Torque Teno Virus (TTV) distribution in healthy Russian population

Contact Info

Product

Resources

About